3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring

Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (NYSE: LLY). Despite more than doubling over the past year, this underappreciated biotech stock could climb a lot further.

A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often overlooked biotech stock. Here's why investors can look forward to outstanding returns from Rigel Pharmaceuticals in the years to come.

Image source: Getty Images.

Continue reading

Source Fool.com